<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-042972</identifier>
<setSpec>0210-5705</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Lamivudine and adefovir resistance in a patient whith hbeag negative chronic hepatitis b</dc:title>
<dc:description xml:lang="en">We have studied a 49-year-old patient with a HBeAg-negative chronic hepatitis B in whom, after 34 months of treatment with lamivudine and associated with an increase in the serum hepatitis B virus (HBV) DNA, the lamivudine resistance mutations M204I and L180V were detected. Lamivudine was substituted for adefovir dipivoxil and after 16 months of treatment, in the course of a study to investigate hepatitis B genotypes, the adefovir resistance mutation N236T was detected. HBV viral load in this sample was 3 ¥ 107 UI/ml. Adefovir is considered as the alternative treatment when lamivudine resistance is detected. Appearance of resistance to adefovir is very unusual and in Spain, no case has been communicated yet. However, we must be aware of the adefovir resistance in patients who do not respond to adefovir and it must be confirmed with a resistance study, if possible</dc:description>
<dc:creator>Moreira, V</dc:creator>
<dc:creator>Mateos, M. L</dc:creator>
<dc:creator>Tato, M</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Paciente de 49 años, diagnosticado de hepatitis crónica B y antígeno e negativo, al que a los 34 meses de tratamiento con lamivudina, y coincidiendo con un aumento de la carga viral del virus de la hepatitis B (VHB), se detectaron las mutaciones M204I y L180V, que confieren resistencia a dicho fármaco. Se cambió el tratamiento a adefovir y a los 16 meses, en un estudio de secuenciación del VHB para conocer su genotipo, se observó la mutación N236T en la región de la retrotranscriptasa, que se asocia con resistencia a adefovir. La carga viral del VHB en sangre en ese momento era de 3 ¥ 107 U/ml. El adefovir se considera el tratamiento alternativo a la lamivudina cuando aparecen resistencias a ésta. Es muy infrecuente la aparición de resistencias al adefovir y en España no se ha publicado todavía ningún caso. Sin embargo, hay que tener en cuenta esta posibilidad en pacientes que no responden al adefovir y confirmarla con un estudio de resistencias del VHB</dc:description>
<dc:source>Gastroenterol Hepatol;29(2): 71-73, feb. 2006. tab</dc:source>
<dc:identifier>ibc-042972</dc:identifier>
<dc:title xml:lang="es">Resistencia del virus de la hepatitis B a lamivudina y adefovir en un paciente con hepatitis crónica B y antígeno e negativo</dc:title>
<dc:subject>^d9346</dc:subject>
<dc:subject>^d^s22073</dc:subject>
<dc:subject>^d33343^s22057</dc:subject>
<dc:subject>^d28093^s22021</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d28093^s22033</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d233^s22073</dc:subject>
<dc:subject>^d36327^s22033</dc:subject>
<dc:subject>^d33070^s22073</dc:subject>
<dc:subject>^d233^s22003</dc:subject>
<dc:subject>^d11184^s22073</dc:subject>
<dc:subject>^d33123</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d6666^s22062</dc:subject>
<dc:subject>^d33343^s22062</dc:subject>
<dc:type>article</dc:type>
<dc:date>200602</dc:date>
</metadata>
</record>
</ibecs-document>
